Combination treatment for hematological cancers
US11278561B2 · kind B2 · utility
0Cited by
25References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 28, 2017 |
| Grant date | Mar 22, 2022 |
| Priority date | — |
| Expiry date | Nov 22, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium and the Bcl-2 inhibitor is ABT-199.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.